Karyopharm Therapeutics (KPTI) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $5.5 million.
- Karyopharm Therapeutics' Accumulated Depreciation & Amortization fell 1765.06% to $5.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.5 million, marking a year-over-year decrease of 1765.06%. This contributed to the annual value of $5.5 million for FY2025, which is 1765.06% down from last year.
- As of Q4 2025, Karyopharm Therapeutics' Accumulated Depreciation & Amortization stood at $5.5 million, which was down 1765.06% from $6.7 million recorded in Q4 2024.
- Karyopharm Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $6.7 million for Q4 2024, and its period low was $5.5 million during Q4 2025.
- In the last 5 years, Karyopharm Therapeutics' Accumulated Depreciation & Amortization had a median value of $6.6 million in 2023 and averaged $6.3 million.
- Per our database at Business Quant, Karyopharm Therapeutics' Accumulated Depreciation & Amortization soared by 1675.02% in 2021 and then plummeted by 1765.06% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Accumulated Depreciation & Amortization stood at $6.1 million in 2021, then grew by 9.71% to $6.6 million in 2022, then fell by 1.2% to $6.6 million in 2023, then increased by 1.92% to $6.7 million in 2024, then fell by 17.65% to $5.5 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $5.5 million for Q4 2025, versus $6.7 million for Q4 2024 and $6.6 million for Q4 2023.